Applied genetics

Ori Biotech and Vineti Form Strategic Partnership to Deliver Integrated Manufacturing and Supply Chain Solutions for Cell and Gene Therapies

Retrieved on: 
Wednesday, May 26, 2021
Life sciences, Branches of biology, Biology, Biotechnology, Applied genetics, Bioethics, Medical genetics, Molecular biology, Therapy, Gene therapy, General Confederation of Labour

Advanced therapies, such as cell therapies, gene therapies, and personalized cancer vaccines, require infrastructure as advanced as their science.

Key Points: 
  • Advanced therapies, such as cell therapies, gene therapies, and personalized cancer vaccines, require infrastructure as advanced as their science.
  • The CGT industry now requires a new level of visibility, detail, and access across each product and facility within the supply chain.
  • This global, non-exclusive partnership between Ori and Vineti, two leading CGT innovators, will provide important solutions for therapy developers, contract manufacturers, and academic centers.
  • Ori is working with leaders across the cell and gene therapy industry to integrate and secure the entire product journey.

The Discovery Labs Signs Foundational Lease with the University of Pennsylvania Gene Therapy Program as Anchor Tenant

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Biology, Life sciences, Molecular biology, Genetic engineering, Applied genetics, Gene delivery, Biotechnology, Gene therapy, Vector, Investigational New Drug

"To welcome Penn's Gene Therapy Program as the anchor tenant for our planned life sciences cluster here in King of Prussia is strong validation for the incredible life science ecosystem that is emerging in Greater Philadelphia."

Key Points: 
  • "To welcome Penn's Gene Therapy Program as the anchor tenant for our planned life sciences cluster here in King of Prussia is strong validation for the incredible life science ecosystem that is emerging in Greater Philadelphia."
  • The Penn Vector Core has deep expertise in state-of-the-art vector technology for basic research applications that advance understanding of gene function and the development of therapeutic vectors.
  • Its new space will support discovery research all the way through submission of Investigational New Drug (IND) applications for clinical trials.
  • The Discovery Labs is the first complete global platform for discovery, development, and delivery of life-changing science and technology.

AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Muscular dystrophy, Biology, Applied genetics, Limb–girdle muscular dystrophy, Emerging technologies, Medical genetics, Molecular biology, Adeno-associated virus, Gene therapy, Calpainopathy, Gene therapy of the human retina

LION-101 is a novel recombinant adeno-associated virus (rAAV) based vector being developed as a one-time intravenous infusion for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9).

Key Points: 
  • LION-101 is a novel recombinant adeno-associated virus (rAAV) based vector being developed as a one-time intravenous infusion for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9).
  • AskBio's gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid and promoter library.
  • Limb-girdle muscular dystrophy: MedlinePlus Genetics
    2 National Institutes of Health -- National Center of Advancing Translational Sciences: Genetic and Rare Diseases Information Center.
  • Limb-girdle muscular dystrophy type 2I | Genetic and Rare Diseases Information Center (GARD) an NCATS Program (nih.gov)
    View original content to download multimedia: http://www.prnewswire.com/news-releases/askbio-announces-ind-for-lion-10...

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

Retrieved on: 
Friday, May 21, 2021
Life sciences, Branches of biology, Biology, Biogen, Spinal muscular atrophy, Applied genetics, Biotechnology, Gene therapy, Therapy, Ginkgo Bioworks

and BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Ginkgo Bioworks today announced a gene therapy collaboration.

Key Points: 
  • and BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Ginkgo Bioworks today announced a gene therapy collaboration.
  • Currently, manufacturing is time-consuming and expensive making it difficult to develop therapies for diseases with high dose needs and with large patient populations.
  • Ginkgo will utilize its bioengineering facilities and resources with the aim of enhancing the AAV production titers of Biogen\xe2\x80\x99s gene therapy manufacturing processes.
  • Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.\n"

Tenaya Therapeutics Receives Orphan Drug Designation and Presents Pre-Clinical Data for its Most Advanced Gene Therapy Product Candidate for Genetic Hypertrophic Cardiomyopathy

Retrieved on: 
Thursday, May 20, 2021
Health, Genetics, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Emerging technologies, Molecular biology, Applied genetics, Medical genetics, Gene therapy

Mutations of this gene are the most common genetic cause of HCM, estimated to represent approximately 19% of the overall HCM population and to affect approximately 115,000 patients in the United States alone.

Key Points: 
  • Mutations of this gene are the most common genetic cause of HCM, estimated to represent approximately 19% of the overall HCM population and to affect approximately 115,000 patients in the United States alone.
  • No safety signals have been observed to date.\n\xe2\x80\x9cWe are pleased that the FDA has granted orphan drug designation for TN-201,\xe2\x80\x9d said Faraz Ali, CEO of Tenaya.
  • Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
  • For more information, please visit www.TenayaTherapeutics.com and follow us on LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210520005683/en/\n'

Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities

Retrieved on: 
Monday, May 17, 2021
Medical devices, Health, Genetics, General Health, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Biotechnology, Applied genetics, Gene delivery, Emerging technologies, Molecular biology, Gene therapy, Viral vector

b"Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc. , a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.

Key Points: 
  • b"Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc. , a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.
  • We look forward to welcoming Vigene\xe2\x80\x99s dedicated employees to the Charles River family.\xe2\x80\x9d\nThe acquisition of Vigene Biosciences will enhance Charles River\xe2\x80\x99s gene therapy capabilities in the high-growth, value-added cell and gene therapy CDMO sector.\nExpands Charles River\xe2\x80\x99s Gene Therapy CDMO Capabilities for Viral Vectors and Plasmid DNA \xe2\x80\x93 Vigene offers its clients contract manufacturing solutions across several key gene therapy platforms, enhancing Charles River\xe2\x80\x99s ability to meet its clients\xe2\x80\x99 evolving scientific needs.
  • Its primary area of expertise is CGMP viral vector manufacturing, which is used for gene therapies and gene-modified cell therapies.
  • Vigene will also support Charles River\xe2\x80\x99s existing, U.S.-based cell therapy production capabilities and establish an end-to-end, gene-modified cell therapy solution.

Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

Retrieved on: 
Friday, May 14, 2021
Branches of biology, Biology, Life sciences, Medical genetics, Emerging technologies, Gene delivery, Molecular biology, Applied genetics, Applied Genetic Technologies Corporation, Gene therapy

b'SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc.\xc2\xa0(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

Key Points: 
  • b'SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc.\xc2\xa0(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
  • OTO-825 is an AAV-mediated gene therapy targeting the gap junction beta-2 (GJB2) gene developed under the company\xe2\x80\x99s collaboration with Applied Genetic Technologies Corporation (Nasdaq: AGTC).
  • The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof.
  • Otonomy disclaims any obligation to update any forward-looking statements, except as required by law.\n'

Luye Life Sciences Unveils Cutting-edge Advances in Gene and Cell Therapy at ASGCT 2021

Retrieved on: 
Friday, May 14, 2021
Branches of biology, Life sciences, Biology, Gene delivery, Genetic engineering, Applied genetics, Emerging technologies, Medical genetics, Gene therapy, Therapy

b'BOSTON, May13, 2021 /PRNewswire/ -- The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, tookpart in the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company\'s latest preclinical developments in gene and cell therapy to the global biological community.\nASGCT is one of the world\'s most influential academic conferences in the area of gene and cell therapy.

Key Points: 
  • b'BOSTON, May13, 2021 /PRNewswire/ -- The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, tookpart in the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company\'s latest preclinical developments in gene and cell therapy to the global biological community.\nASGCT is one of the world\'s most influential academic conferences in the area of gene and cell therapy.
  • Sean Fu, President of Luye Life Sciences Boston R&D Center, and CEO of GeneLeap Biotech, said, "This is the first time that we have presented information on the progress of our scientific research in gene and cell therapy at the ASGCT annual meeting.
  • "\nThe R&D center at Boston, Woburn, MA is a subsidiary of Luye Life Sciences, developing novel drugs for cancer and genetic disorders, including gene therapy, immune checkpoint inhibitory antibodies, CAR-T cells therapy, and novel drug delivery mechanisms.
  • At present, the AAV platform for gene therapy program developed by the Boston R&D center has several candidates in the pipeline.\nGeneLeap Bio., a subsidiary of Luye Life Sciences, specializes in developing gene therapy drugs for cancer and severe infectious diseases, including mRNA and oligonucleotides.

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Medical specialties, Clinical medicine, Vaccines, Cancer vaccines, Genomics, Applied genetics, Biotechnology, Immunogenicity, Mutanome, Epitope, Antigen

b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.

Key Points: 
  • b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.
  • This study demonstrates a superior method of survival analysis for cancer patients using EVT\'s Ancer platform.
  • EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools to clinical research.\nBuilt on validated in silico tools EpiMatrix and JanusMatrix , Ancer analyzesindividual cancer mutanomes to definethe presence of T cell epitopes likely to be immunogenic.
  • EVT\'s pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.\n'

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Medical specialties, Clinical medicine, Vaccines, Cancer vaccines, Genomics, Applied genetics, Biotechnology, Immunogenicity, Mutanome, Antigen, Cancer vaccine

b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.

Key Points: 
  • b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.
  • This study demonstrates a superior method of survival analysis for cancer patients using EVT\'s Ancer platform.
  • EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools to clinical research.\nEpiVax Therapeutics researchers develop improved method for cancer survival prediction.\nBuilt on validated in silico tools EpiMatrix and JanusMatrix , Ancer analyzesindividual cancer mutanomes to definethe presence of T cell epitopes likely to be immunogenic.
  • EVT\'s pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/improving-cancer-survival-predic...\n'